Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A regulatory committee has recommended that the European Medicines Agency approve AbbVieâ€™s â€œ3Dâ€ regimen to treat genotypes...
AbbVie’s ’3D’ regimen plus ribavirin cured all people with genotype 4 of hepatitis C in a recent trial, plus 91 percent of those with genotype...
AbbVie’s investigatory ’3D’ hepatitis C treatment regimen rapidly improves indicators of liver health among those with cirrhosis.
The FDA has approved Gilead Sciences’ hotly anticipated new hepatitis C therapy Harvoni (ledipasvir/sofosbuvir).
Bristol-Myers Squibb has decided to end its pursuit of an approval for the hepatitis C therapy asunaprevir in the United States.
AbbVieâ€™s â€œ3Dâ€ regimen cured high rates of genotype 1 of hepatitis C virus (HCV) among people coinfected with HIV.
As a new crop of hepatitis C therapies likely hits the market this fall, Gilead Sciences is poised to continue dominating the field.
AbbVie’s 3D hepatitis C regimen is safe for use with opioid replacement therapy to treat drug addiction.
AbbVie?s ?3D? regimen has shown high cure rates in treating genotype 1 of hepatitis C among those coinfected with HIV, both with and without c...
With interferon quickly becoming a thing of the past, what kind of side effects still remain in the new hepatitis C regimens?
The U.S. Food and Drug Administration has granted AbbVie’s so-called ’3D’ hepatitis C treatment “priority review” status.
Combo cured all study participants who had genotype 1b of hep C, did not have cirrhosis and had previously failed interferon-based treatment
AbbVie’s ’3-D’ regimen has had nearly perfect preliminary results in curing people with recurrent geno 1 of hep C post-liver transplant.
AbbVie submitted a new drug application to the FDA for its 3D combination regimen of antivirals to treat adults with genotype 1 of HCV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.